return to news
  1. Upstox
    /
  2. News
    /
  3. Market News
    /
  4. Stocks
    /
  5. Torrent Pharma shares soar 6% to 52-week high post Q3 results, dividend declared; check numbers

Market News

Torrent Pharma shares soar 6% to 52-week high post Q3 results, dividend declared; check numbers

Abha Raverkar
By Abha Raverkar

3 min read | Updated on February 16, 2026, 13:59 IST

Twitter Page
Linkedin Page
Whatsapp Page

SUMMARY

Torrent Pharma Q3 results: Its revenue from operations advanced 17.59% YoY to ₹3,303 crore for the December quarter of FY26, compared to ₹2,809 crore in the same period of FY25.

Stock list

TORNTPHARM
--
Torrent Pharma Ltd

Torrent Pharma reported a 26.24% YoY surge in its consolidated net profit to ₹635 crore for the December quarter of FY26. | Image: Shutterstock

Torrent Pharma share price: Shares of drug manufacturer Torrent Pharmaceuticals rallied as much as 6.05% to a fresh 52-week high of ₹4,324.90 apiece on the National Stock Exchange (NSE) on Monday, February 16.
Open FREE Demat Account within minutes!
Join now

This comes after the company posted its earnings for the third quarter of the 2025-26 financial year (Q3FY26) in post-market hours on Friday.

At around pm, the stock was trading % higher at ₹ per equity share. It had touched a year’s low of ₹2,886.45 per unit on March 3, 2025.

Torrent Pharma Q3 results

The Gujarat-headquartered company reported a 26.24% year-on-year (YoY) surge in its consolidated net profit to ₹635 crore for the December quarter of FY26.

In the corresponding period of the previous fiscal year, it had logged a profit of ₹503 crore, it said in a regulatory filing on Friday.

Its revenue from operations advanced 17.59% YoY to ₹3,303 crore for the reporting quarter, compared to ₹2,809 crore in the third quarter of the 2024-25 fiscal year (Q3FY25).

On a geographical basis, its revenue from the India business grew 14% YoY to ₹1,798 crore, in comparison to ₹1,581 crore.
The US market revenue increased by 19% YoY to ₹321 crore, from ₹271 crore. Its revenue in constant currency terms was at $36 million, up by 12% compared to the same period in the previous year, with recent launches helping to achieve target market shares.
It clocked a revenue of ₹304 crore from the Germany segment, up by 8% YoY from ₹282 crore, with growth being impacted due to supply disruption at a third-party supplier.
Its revenue from the Brazil market soared 27% to ₹371 crore, in contrast to ₹291 crore in Q3 FY25. As per IQVIA, Torrent grew at 13% in the Brazilian market, compared to a market growth of 7%, aided by the performance of top brands & recent launches.
Furthermore, its revenue from other markets was at ₹509 crore, marking a 32% YoY jump from ₹384 crore.

At an operational level, its EBITDA (earnings before interest, tax, depreciation and amortisation), also known as operating profit, stood at ₹1,088 crore in Q3 FY26, reflecting a 19% YoY increase from ₹914 crore in the year-ago period. Its EBITDA margin remained flat at 33% on a YoY basis.

Board approves interim dividend

The board of directors of Torrent Pharma also declared an interim dividend of ₹29 per equity share (580%), of ₹5 fully paid up.

It also stated that the dividend is expected to be paid or dispatched on or around March 6, 2026.

Torrent Pharmaceuticals has a total market capitalisation of ₹1.44 lakh crore, as of February 16, 2026, according to data on the NSE.

To add Upstox News as your preferred source on Google, click here.
SIP
Consistency beats timing.
promotion image

About The Author

Abha Raverkar
Abha Raverkar is a post-graduate in economics from Christ University, Bengaluru. She has a strong interest in the markets and loves to unravel the nitty-gritties of the latest happenings in the world of markets, business, and the economy.

Next Story